FindTrial
Sign In

Does combination of metformin together with myoinositol and D-chiroinositol improve clinical, metabolic and hormonal parameters in women with polycystic ovaries

Comparison of clinical, metabolic and hormonal effects of metformin versus combined therapy with metformin and myoinositol and D- chiro-inositol in women with polycystic ovary

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/013977
Enrollment
72
Registered
2018-05-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Polycystic Ovarian Syndrome

Interventions

Intervention1: metformin and myoinositol and D- chiro-inositol: Patients in Group II will receive metformin 500 mg twice a day along with Myo-inositol 550 mg + D-chiro-inositol 150 mg twice daily for

Sponsors

AIIMS Rishikesh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Women in the reproductive age group with Polycystic ovarian syndrome (PCOS), according to Rotterdam criteria 2.Willing to participate in study and follow up

Exclusion criteria

Exclusion criteria: • Patient already on other drugs for treatment of PCOS like Oral Contraceptive Pills • Deranged kidney or liver function tests • Uncontrolled Thyroid disorders or Hyperprolactinemia • Known hypersensitivity to metformin or myoinositol/ D-Chiro-inositol

Design outcomes

Primary

MeasureTime frame
primary end point in this study will be-post prandial endogenous insulin levelsTimepoint: primary end point in this study will be-post prandial endogenous insulin levels—

Secondary

MeasureTime frame
A. Improvement in clinical parameter includes 1. menstrual cycle irregularity 2. BMI 3. Waist : Hip ratio 4. Hirsutism/acne B. Improvement in Metabolic and hormonal parameters includes 1. Lipid profile 2. Blood sugar fasting and post prandial 3. Insulin fasting and post prandial 4. Glucose to insulin ratio 5. LH/FSH ratio 6. Serum Testosterone 7. DHEAS 8. HOMA IR IndexTimepoint: At the end of 6 months—

Countries

India

Contacts

Public ContactDr Hitanshi Arora

All India Institute of Medical Sciences Rishikesh

anupama.bahadur@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026